baricitinib · Eli Lilly And Co · NDA 207924
Olumiant
Earliest generic entry, as listed · earliest of 3 marketed strengths
30 Nov 2032
Blocked by patent: US 11045474, US 9089574. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11045474 | use U-3372 | 30 Nov 2032 |
| US 9089574 | use U-3372 | 30 Nov 2032 |
| US 8158616 | substance, product | 31 May 2032 |
| US 11806555 | use U-3500 | 2 Nov 2031 |
| US 9737469 | use U-3500 | 2 Nov 2031 |
| US 8420629 | use U-247 | 10 Mar 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207924 · 001 · RLD | tablet, oral | 2MG | 30 Nov 2032 |
| 207924 · 002 · RLD | tablet, oral | 1MG | 30 Nov 2032 |
| 207924 · 003 · RLD | tablet, oral | 4MG | 30 Nov 2032 |